Arcutis Presents Positive Patient-Reported Outcome Data for ZORYVE® (Roflumilast) Cream 0.15% in Atopic Dermatitis at American College of Allergy, Asthma and Immunology 2024 Annual Scientific Meeting Arcutis today announced new patient-reported outcome data demonstrating that ZORYVE cream 0.15% improved the impact of AD on patients and families.

Intrommune Therapeutics Presents Positive Results of Phase 1 OMEGA Study Investigating the Safety of INT301 Toothpaste for the Treatment of Peanut Allergy Intrommune Therapeutics Presents Positive Results of Phase 1 OMEGA Study Investigating the Safety of INT301 Toothpaste for the Treatment Peanut Allergy

USA Equities Corp. Introduces AllergiQT™ – Quick Test, Further Expanding Market Presence FDA-cleared and Easily Administered Skin Test for Environmental and Food Allergens; AllergiQT™ – Quick Test Targets Non-Allergy Specialists in Primary Care SettingsStrengthens USA Equities...

Certification Program Science and Standards give a unique platform for research at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting in Boston Dublin, Ireland, Nov. 03, 2017 (GLOBE NEWSWIRE) -- This year, the annual meeting was also celebrating ACAAI’s 75th anniversary. For the occasion ASL’s joint venture program exhibited, alongside the...